We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Bausch Health Companies Inc (BHC) NPV

Sell:$23.83 Buy:$23.84 Change: $0.48 (1.97%)
Market closed |  Prices as at close on 26 January 2022 | Switch to live prices |
Sell:$23.83
Buy:$23.84
Change: $0.48 (1.97%)
Market closed |  Prices as at close on 26 January 2022 | Switch to live prices |
Sell:$23.83
Buy:$23.84
Change: $0.48 (1.97%)
Market closed |  Prices as at close on 26 January 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Bausch Health Companies Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. Its segments include Bausch + Lomb, Salix, Ortho Dermatologics, International Rx and Diversified Products. The Bausch + Lomb segment consists of sales in the United States of Bausch + Lomb Vision Care, Consumer, Surgical and Ophthalmology Rx products. The Salix segment consists of sales in the United States of gastroenterology (GI) products. The Ortho Dermatologics segment consists of sales in the United States of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices.

Contact details

Address:
2150 Saint-Elzear Blvd W
LAVAL
H7L 4A8
Canada
Telephone:
+1 (514) 7446792
Website:
https://www.bauschhealth.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BHC
ISIN:
CA0717341071
Market cap:
$8.74 billion
Shares in issue:
359.33 million
Sector:
Pharmaceuticals
Exchange:
New York Stock Exchange
Country:
Canada
Currency:
US dollar
Indices:
n/a

Key personnel

  • Joseph Papa
    Chairman of the Board, Chief Executive Officer
  • Sam Will
    Chief Financial Officer, Executive Vice President
  • Thomas Appio
    President and Co-Head Bausch + Lomb/International
  • Joseph Gordon
    President and Co-Head Bausch + Lomb/International
  • Robert Spurr
    President - Salix
  • Christina Ackermann
    Executive Vice President, General Counsel and Head of Commercial Operations
  • Paul Herendeen
    Executive Vice President

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.